Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Sprifermin promotes cartilage growth, and could be a potential disease modifying treatment for osteoarthritis.
January 10, 2022
By: Kristin Brooks
Managing Editor, Contract Pharma
TrialSpark has formed High Line Bio following the acquisition of worldwide rights to sprifermin from Merck KGaA, Darmstadt, Germany. Sprifermin is a potential first-in-class disease modifying anti-FGF 18 monoclonal antibody that is being evaluated as a potential treatment for osteoarthritis (OA) by promoting cartilage growth. Cartilage loss is an important component in the development of OA, a degenerative joint disease with unmet medical needs. As the first monoclonal antibody to demonstrate cartilage growth in a controlled clinical study, Sprifermin is on the forefront of next generation regenerative medicine with the potential to modify the underlying disease pathology in OA. To date, Merck KGaA has completed three clinical trials in over 800 patients, including the 549-patients Phase 2 FORWARD trial. TrialSpark will be responsible for future development and commercialization of sprifermin. As part of the agreement Merck KGaA will receive an upfront payment as well as equity in High Line Bio, and is eligible for clinical and commercial milestones in addition to royalties. Full financial terms were not disclosed. High Line Bio will leverage TrialSpark’s tech-enabled clinical trial engine to develop sprifermin in OA using a data-driven approach to identifying novel biomarkers, endpoints, and patient subgroups most likely to benefit from the therapy. TrialSpark is also partnering with industry leaders such as SomaLogic to leverage precision genomics and proteomics platforms to identify key biomarkers and stratify patients using synovial fluid samples from prior clinical studies using AI and machine-learning approaches. Beyond sprifermin, High Line Bio also plans in-license additional complementary products to build a differentiated pipeline focused on OA and regenerative medicine.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !